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AN INVESTIGATION OF THE PROGRESSION FROM BARRETT’S 
ESOPHAGUS TO ADENOCARCINOMA  
SCOTT PALMESE 
 
ABSTRACT 
 
Barrett ‘s esophagus is a metaplasia of the epithelium of the lower esophagus 
from a normal squamous appearance to a columnar appearance more typically found in 
the stomach.  It is normally caused by prolonged gastric reflux.  While Barrett’s 
esophagus is not usually the direct cause of adverse symptoms, it does put a person at 
greater risk for developing esophageal adenocarcinoma, one of the least treatable cancers 
currently known. 
 While the progression from gastric reflux to Barrett’s esophagus is fairly clear, 
the relationship between Barrett’s esophagus and esophageal adenocarcinoma is not as 
well understood.  Not all patients diagnosed with Barrett’s esophagus will go on to 
develop esophageal adenocarcinoma.  There are several factors that may have some 
impact on this progression, including obesity, lifestyle, and genetic predisposition.  The 
purpose of this study was to evaluate the literature to determine the potential impacts of 
each of these factors on development of esophageal adenocarcinoma.   
While obesity and lifestyle clearly have some impact on development of 
esophageal adenocarcinoma, it was found that the exact nature of that impact is still 
unclear.  Obesity leads to several consequences, including increased gastroesophageal 
  v 
reflux, hormonal changes, and reduction in the bacterium H. pylori, all of which have 
been shown to have some impact on metaplasia in the esophagus.  Lifestyle choices, 
including alcohol or tobacco use, also have been shown to have at least some effect on 
development of esophageal adenocarcinoma. 
The literature also reveals that inherited risk factors, namely genetic 
predisposition, may play a role in development of esophageal adenocarcinoma.  Genetic 
predisposition to obesity may have some impact, but other studies have identified genetic 
variations that seem to directly influence development of esophageal adenocarcinoma. 
While it is clear that there are several factors that influence development of 
esophageal adenocarcinoma, we do not yet understand the complete etiology.  By 
continuing to study these risk factors, we will be able to develop new treatments to 
combat the rising incidence of Barrett’s esophagus and esophageal adenocarcinoma. 
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 1 
INTRODUCTION 
 
What is Barrett’s Esophagus? 
 
 Barrett’s esophagus is a disease state that arises primarily as a complication of 
gastroesophageal reflux (Stein and Siewert, 1993).  It is characterized by a metaplasia in 
the distal esophagus, a change in cell lining from the normal stratified squamous 
epithelium to a columnar epithelium more common to the stomach (Clemons, 2014).  The 
disease state is more common in men than women and is strongly associated with central 
obesity (Reid, 2010).  While Barrett’s esophagus does not necessarily constitute a cause 
for immediate concern, it must be carefully monitored because it increases a person’s 
predisposition for the development of esophageal cancer (Kumar, 2013). 
Previous studies have shown that obesity and lifestyle are two of the most 
significant risk factors for the development of gastroesophageal reflux, and, 
consequently, the progression to Barrett’s esophagus.  The link between Barrett’s 
esophagus and adenocarcinoma is a little less clear. 
 This paper will first describe the history of the condition, before delving into the 
normal physiology of the esophagus and stomach.   Next the etiology of gastroesophageal 
reflux and, subsequently, Barrett’s esophagus will be described.  While this progression 
is mostly understood, it is less clear how Barrett’s esophagus leads to esophageal cancer.  
This literature review will attempt to elucidate the connection between Barrett’s 
esophagus and development of adenocarcinoma.  Specifically: 
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1) How do diet, lifestyle, and other potentially modifiable factors contribute to 
the development of adenocarcinoma once a patient has been diagnosed with 
Barrett’s esophagus?  Is there any evidence to suggest that diet and lifestyle 
changes can improve the prognosis of a patient already diagnosed with 
Barrett’s esophagus by preventing the development of esophageal cancer? 
2) Are there any specific genetic markers that can identify patients predisposed 
to the development of cancer from an existing diagnosis of Barrett’s 
esophagus?  How does genetics play a role in the development of 
adenocarcinoma? 
3) Is there a way to reverse the metaplasia or dysplasia associated with Barrett’s 
esophagus?  Can current knowledge about the mechanism of development of 
adenocarcinoma help shed light on possible new treatments? 
By clarifying the relationship between Barrett’s and development of cancer, this review 
will hopefully serve as a resource for medical professionals with patients suffering from 
these conditions. 
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BACKGROUND 
 
The History of Barrett’s Esophagus 
 
 Barrett’s esophagus was first described by thoracic surgeon Norman Barrett in 
1950 and it wasn’t until 1953 that a link was made between gastroesophageal reflux and 
the development of the metaplasia (Barrett, 1950; Allison and Johnstone, 1953).  For 
several years, physicians could not determine any negative effects arising from the 
development of this condition, as there were usually no additional symptoms other than 
those traditionally associated with acid reflux.  Endoscopic procedures, however, clearly 
showed a visually distinct pattern in the lower esophagus that was not present in all 
patients suffering from gastroesophageal reflux [Figure 1].  It wasn’t until 1975 that 
Barrett’s esophagus was described as a premalignant state, a condition that puts patients 
at a greater risk for developing adenocarcinoma of the esophagus (Naef et al, 1975). 
 
Normal Physiology of the Esophagus and Stomach 
 
 The main function of the esophagus, along with the upper and lower esophageal 
sphincters, is to propel food from the mouth to the stomach and to prevent reflux from the 
stomach.  In other words, the esophagus is designed to make sure anything entering the 
mouth only travels in one direction – towards the stomach for the start of the digestive  
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process.  The esophagus is lined by stratified squamous epithelium, a thick type of 
epithelium that is ideal for areas of the body subject to abrasive forces.  In the esophagus, 
the epithelium is regenerated as the outer layers are sloughed off as food travels toward 
the stomach (Marieb et al, 2013). 
There are three major structures that make up the esophagus: the upper 
esophageal sphincter, the body, and the lower esophageal sphincter (Yazaki and Sifrim, 
2011).  The lower esophageal sphincter is of most interest to this investigation, as it is the 
junction between the esophagus and the stomach [Figure 2].   
Figure 1. Endoscopic image of the classic appearance of 
Barrett’s esophagus in the lower esophagus.  The darker 
pink coloring of the epithelium in this image represents the 
cells that have undergone a metaplasia from the normal 
squamous appearance of the esophagus to the columnar 
appearance of the stomach.  The lighter pink coloring 
represents the normal squamous epithelium of a healthy 
esophagus.  (Figure taken from Badreddine and Wang, 2010). 
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The lower esophageal sphincter is surrounded by smooth muscle, and is normally 
innervated by both excitatory and inhibitory neurons.  While the full functionality of the 
lower esophageal sphincter is not yet understood, it is clear that there is a myogenic 
property of the smooth muscle associated with this region.  This property keeps the  
Figure 2. Anatomical depiction of the lower esophageal 
sphincter.  This image depicts the lower esophageal sphincter 
(LES), the junction between the esophagus and the stomach.  
Myogenic (muscle-originating) input from the surrounding 
smooth muscle, depicted here in two layers (a longitudinal 
layer and a circular layer), keeps the LES closed.  Contraction 
and relaxation of the diaphragm also is involved in the normal 
functioning of the LES.  The squamocolumnar junction is the 
anatomical “line” between the stratified squamous epithelium 
of the esophagus and the columnar epithelium of the stomach.  
If Barrett’s esophagus develops, this “line” will move 
proximally into the body of the esophagus.  (Figure taken 
from Yazaki and Sifrim, 2011). 
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sphincter tonically closed and the excitatory and inhibitory neurons appear to modulate 
this activity (Goyal and Rattan, 1975; Goyal and Chaudhury, 2008).  Malfunction in this 
neural input could account for development of esophageal reflux, disrupting the normal 
tonic closure and allowing acids from the stomach to enter the esophagus (Powley et al, 
2013). 
 The stomach, unlike the esophagus, is lined by a simple columnar epithelium.  
This type of epithelium lines most of the gastrointestinal tract, and is responsible for the 
secretion of digestive enzymes.  Most importantly, columnar epithelium is much more 
resistant than squamous epithelium to hydrochloric acid and pepsin, two enzymes 
regularly secreted in the stomach.  It is believed that the metaplasia observed in Barrett’s 
esophagus is a defense mechanism by the body in reaction to the abnormal presence of 
stomach acid in the lower esophagus.  Columnar epithelium is better equipped to prevent 
stomach acids from penetrating the deeper layers of the inner esophageal lining 
(International Foundation for Functional Gastrointestinal Disorders, 2014). 
 
 
Development of Gastroesophageal Reflux    
 In order to understand the transition from Barrett’s esophagus to adenocarcinoma, 
it is important to first understand the development of gastroesophageal reflux (GERD), 
the first stage in the progression to Barrett’s esophagus.  GERD affects 10-20% of the 
western world and is not always cause for concern (Hershcovici and Fass, 2011).  Many 
people experience reflux occasionally, however, reflux occurring more than twice a week 
 7 
may be an indication of a chronic problem (Mayo Clinic, 2014).  A current official 
definition of GERD explains it as “a condition which develops when the reflux of 
stomach contents causes troublesome symptoms (i.e. at least two heartburn episodes per 
week) and/or complications” (Vakil et al, 2006).  While regurgitation and heartburn are 
the most common symptoms of GERD, other less universal symptoms include sore 
throat, nausea, chest pain, and coughing (Kahrilas et al, 2000). 
 As discussed previously, GERD is usually caused by impairment of the lower 
esophageal sphincter, the part of the gastrointestinal tract that separates the lower 
esophagus from the upper portion of the stomach.  The angle at which the esophagus 
enters the stomach is called the Angle of His.  In healthy individuals, this angle creates a 
narrowing in this part of the esophagus, essentially creating a valve.  This structure, in 
conjunction with the lower esophageal sphincter, helps to prevent stomach acid from 
entering the esophagus.  The Angle of His develops as an individual ages.  This angle 
usually is not fully developed during infancy, a primary reason why gastric reflux is 
relatively common in infants (Sircar, 2008). 
Many times GERD is caused partially by a hiatal hernia.  A hiatal hernia is a 
protrusion of the stomach through the esophageal opening in the diaphragm (Van 
Weyenberg, 2006).  This increases the pressure observed in vivo in the stomach relative 
to the pressure observed in the esophagus, causing the lower esophageal sphincter to be 
open at times when it should be closed (Pettersson et al, 1981; de Vries et al, 2008;  
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Kahrilas et al, 2000) [Figure 3].  When the lower esophageal sphincter is open at the 
wrong time, gastroesophageal reflux results. 
Figure 3.  Relationship of gastric and esophageal pressure 
in the presence and absence of a hiatal hernia.  “A” 
represents the relationship of pressure (in cm H2O) with time 
after a gastric infusion of both the esophagus and stomach in a 
healthy apparatus in vivo.  “B” represents the relationship of 
pressure with time after a gastric infusion in the presence of a 
hiatal hernia.  In “B”, there is a greater disparity between 
gastric pressure and esophageal pressure, causing a large  
pressure gradient between the two regions of the 
gastrointestinal tract.  Due to this larger gradient, the gastric 
infusion (and consequently other gastric juices) are more 
inclined to be pushed from the stomach to the esophagus.  
This illustrates the impact of a hiatal hernia on the 
development of gastroesophageal reflux (Figure taken from 
Pettersson et al, 1981).  
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Diagnosis and Treatment of Gastroesophageal Reflux 
 
 While reflux typically causes the symptoms outlined above, it is not always 
symptomatic.  A proper diagnosis of gastroesophageal reflux disease requires the patient  
to be symptomatic and to have reflux of stomach contents into the esophagus (Kahrilas et 
al, 2008).  The current gold standard for diagnosis is esophageal pH monitoring.  In many 
cases, pH monitoring is used to track pH changes in a subject’s esophagus during a 
period of short-term proton pump inhibitor treatment.  The pH within the esophagus is 
measured before, during, and after treatment in order to determine the effect of proton 
pump inhibitors.  To do this, a thin tube with an attached monitor is passed through the 
mouth or nose into the subject’s stomach.  Once the tube is in the stomach, it is pulled 
back into the lower esophagus.  The monitor records the pH of the acid content in the 
lower esophagus for 24 hours before the tube is removed.  The concentration of protons 
(H
+
), by definition, determines the acid content of a solution.  Proton pump inhibitors 
decrease gastric acid content by decreasing the concentration of protons being pumped 
into the lumen of the gastrointestinal tract – in this case the stomach.  By treating a 
patient with proton pump inhibitors and decreasing the amount of gastric acid available 
for reflux (tracked by the aforementioned pH monitoring), a determination of the 
presence or absence of gastroesophageal reflux could be determined by a change in 
symptoms.  An improvement of symptoms would suggest that GERD is indeed present 
(Numans, M.E. et al, 2004; Medline Plus, 2012). 
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 Proton pump inhibitors are usually the first line of treatment for gastroesophageal 
reflux for the reasons described above.  If proton pump inhibitors do not lead to a 
significant improvement of symptoms, surgical intervention may be required to improve 
the patient’s quality of life and decrease the likelihood that the reflux will lead to 
Barrett’s esophagus or esophageal adenocarcinoma.  The most common surgery is called 
the Nissen fundoplication, and it is only recommended for patients that have seen at least 
some benefit from the use of proton pump inhibitors (Katz et al, 2013). 
 The Nissen fundoplication works to correct two potential problems that may have 
initially led to the development of gastroesophageal reflux: a weak lower esophageal 
sphincter and a hiatal hernia [Figure 4].  The upper portion of the stomach is called the 
fundus, hence the name of the surgical procedure.  During the surgery, the fundus of the 
stomach is wrapped around the lower esophagus, reinforcing the sphincter to improve 
closing functionality and preventing the stomach from protruding through the diaphragm.  
When a patient who has had this procedure is attempting to digest food, the stomach will 
contract and, since it would now be wrapped around the esophagus, the lower esophagus 
would be forced to contract as well.  This would prevent gastric acids from entering the 
esophagus.  Additionally, the opening of the lower esophagus is tightened so that a hiatal 
hernia can be improved or, ideally, completely eliminated (Nissen, 1961; Abbas et al, 
2004). 
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Figure 4.  Diagram illustrating a Nissen Fundoplication.  
The goal of a Nissen Fundoplication is to treat a patient 
suffering from gastroesophageal reflux.  The upper portion of 
the stomach (the fundus) is wrapped around the lower 
esophagus, strengthening the lower esophageal sphincter.  In 
addition, any contraction of the stomach during food digestion 
will also contract the lower esophagus, preventing acid reflux 
from occurring.  Figure taken from 
http://www.illustratedverdict.com/projectreview/IllustratedVe
rdict_2011v3.asp). 
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The Progression from Gastroesophageal Reflux to Barrett’s Esophagus 
  
 Gastroesophageal reflux, as described in the previous sections, sometimes leads to 
Barrett’s esophagus.  Barrett’s esophagus and its complications (namely its link to 
adenocarcinoma) will be the focus of the remainder of this investigation.  Barrett’s 
esophagus is not a condition that occurs spontaneously and it is relatively rare in the 
population.  While it is strongly linked to gastroesophageal reflux, a majority of patients 
suffering from gastroesophageal reflux do not develop Barrett’s esophagus.  Only about 
10-20% of patients suffering from gastroesophageal reflux actually exhibit the metaplasia 
associated with Barrett’s esophagus (Modiano and Gerson, 2007). 
Unfortunately, the rising incidence of obesity in the population, especially in parts 
of the Western world, is contributing to a rise in Barrett’s esophagus.  Obesity leads to an 
increase in intra-abdominal pressure, which distorts the junction between the esophagus 
and the stomach.  Ultimately, this may lead to a hiatal hernia or other disruptions of the 
lower esophageal sphincter.  This contributes greatly to gastric reflux, which in turn leads 
to Barrett’s esophagus (Lee and McColl, 2014).  Strangely, Barrett’s esophagus has also 
been present in patients who do not exhibit gastroesophageal reflux, though this is less 
understood (Shaheen and Richter, 2009). 
 Both macroscopic and histological features must be present in order to make a 
definitive diagnosis of Barrett’s esophagus.  An endoscopic investigation of the lower 
esophagus will clearly show a difference in cell type if Barrett’s esophagus is present 
because the lumen walls will be of a different color [Figure 1].  Most importantly, the 
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altered histology must be observed as well with a tissue sample.  As discussed previously, 
a positive result for Barrett’s esophagus would show a columnar epithelium usually 
native to the stomach rather than a stratified squamous epithelium typically found in the 
esophagus (Flejou, 2005). 
The key to dealing with gastroesophageal reflux is keeping it under control 
through both lifestyle changes (diet, exercise, etc.) and medical intervention, as discussed 
previously.  While gastroesophageal reflux does cause damage to the luminal walls of the 
lower esophagus, it does not do so all at once.  Instead, the metaplasia associated with 
Barrett’s esophagus happens gradually, and it may not even happen at all [Figure 5].  
Even for those who do develop Barrett’s esophagus, the time it takes to develop the 
condition once diagnosed with GERD varies.  The progressive etiology leading to cancer 
can be halted and even reversed if it is caught before any metaplasia takes place through 
the normal regeneration of the esophagus’ squamous epithelium. 
 
Barrett’s Esophagus to Cancer: an Overview 
 
While the exact pathogenesis from Barrett’s esophagus to cancer is not 
understood, it seems that cancer arising from Barrett’s esophagus is due to a change from 
metaplasia to dysplasia.  Dysplasia is the proliferation of immature cells that would not 
normally be found in large numbers in an adult.  The cancer most commonly associated 
with Barrett’s esophagus, adenocarcinoma, is characterized by several changes at the 
genomic level.  Many genes commonly associated with a variety of cancers, including  
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Figure 5. Progression of gastroesophageal reflux to 
Barrett’s esophagus.  Prolonged gastroesophageal reflux will 
cause a metaplasia (change in cell type) in the esophagus 
from a squamous epithelium to a columnar epithelium, 
characteristic of Barrett’s esophagus.  If treated early enough, 
reflux may not lead to Barrett’s esophagus and affected cells 
will heal and assume the normal esophageal appearance 
(Figure taken from Stein and Siewert, 1993). 
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tumor suppressor genes p53 and p16, have been shown to be defective in patients with 
adenocarcinomas (Koppert et al, 2005).  
For a patient that has developed Barrett’s esophagus, the standard procedure is to 
have routine endoscopies to monitor for development of cancerous tissue.  Depending on 
the degree of cellular abnormality upon diagnosis, the patient may be advised to see a 
doctor anywhere from once every few months to once every five years (American 
Gastroenterological Association, 2014).  While it is well documented that diet, exercise, 
and other lifestyle interventions can improve reflux, it is unclear whether or not those 
changes alter the progression or risk of an adenocarcinoma.  Currently, researchers are 
attempting to determine why some patients with Barrett’s esophagus develop cancer 
while others do not.  Presumably, if a direct link is found between Barrett’s and cancer, 
treatment can be better directed towards specific patients (Muthusamy and Sharma, 2011; 
Lee and McColl, 2014)
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DISCUSSION OF PUBLISHED STUDIES 
 
Since it was first discovered that there is a link between development of Barrett’s 
esophagus and esophageal cancer, major risk factors have been identified that may 
provide some clarity on the etiology of adenocarcinoma of the esophagus.  A few of these 
risk factors, obesity and lifestyle, are attributes that are modifiable, while another, genetic 
predisposition, is not something that can be altered.  These risk factors will now be 
discussed in detail, with a focus on previously published studies in the field.  Finally, this 
investigation will explore current cutting-edge treatments and discuss how our knowledge 
of the risk factors may help decrease the rising incidence of esophageal adenocarcinoma. 
 
Obesity: General Implications 
 
The incidence of esophageal adenocarcinoma and the incidence of obesity have 
both increased markedly since the 1970s, trends that first caused researchers to look into 
a possible correlation.  Even today, the relationship between obesity and adenocarcinoma 
is not fully understood, and many recent studies have published widely varying 
conclusions on the exact nature of the impact of obesity on development of esophageal 
cancer.  Researchers have, however, identified several consequences of obesity that may 
have some impact on the development of esophageal adenocarcinoma [Figure 6].  Each 
of these factors will be explored in this investigation. 
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In 2014, Long and Beales published a review in which they conducted a meta-
analysis of 22 studies looking at the relationship between body mass index (a standard 
measure of obesity) and risk for development of esophageal adenocarcinoma.  They 
found that relative risk of developing adenocarcinoma was almost three times higher in 
individuals with body mass indices greater than 30 kg/m
2
.  In addition, they found that 
Figure 6. A summary of the interrelated factors between 
obesity and the progressive etiology leading to 
development of esophageal adenocarcinoma.  While it is 
not understood exactly how obesity affects the development 
of esophageal adenocarcinoma, there are several factors that 
may play a role.  Several consequences of obesity, including 
increased gastroesophageal reflux, hormonal changes, and 
decreased H. pylori may lead to an increased risk of 
developing adenocarcinoma.  Lifestyle and dietary habits may 
reverse or strengthen the trend towards development of cancer 
as well.  (Figure taken from Alexandre et al, 2014). 
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the relative risk increased (RR = 1.11) for every 5 kg/m
2
 increase in body mass index 
among subjects in this study.  These relationships held true for both men and women. 
The results compiled by Long and Beales were also stratified to separate those 
also experiencing gastroesophageal reflux.  They found that the same relationships held 
true, even when reflux was not taken into account.  This implies that obesity has an 
impact on development of esophageal adenocarcinoma independent of the impact of 
gastric reflux.  Since individuals with Barrett’s esophagus usually are suffering from 
gastroesophageal reflux, it can be concluded that obese individuals have a higher relative 
risk for adenocarcinoma than those who have Barrett’s but are not obese.    
 
Obesity: Associated Hormonal Changes 
 
In an obese individual, levels of certain hormones have been found to be, in many 
cases, much different than levels of the same hormones in non-obese individuals.  Two of 
the primary hormones that are affected are adiponectin and leptin, two substances 
normally secreted from the body’s adipose tissue.  These two hormones function to 
regulate appetite and body mass.  When an individual is obese, that person usually 
secretes a greater concentration of leptin and conversely a lower concentration of 
adiponectin.  Insulin, the hormone usually most closely associated with obesity, also 
increases in obese patients.  Obesity is often said to be caused by either a leptin or insulin 
resistance, since levels of these hormones usually rise while appetite and nutrient 
regulation fail. 
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Duggan et al. (2013) investigated the association between leptin, adiponectin, and 
insulin levels and the development of adenocarcinoma in a cohort of patients already 
diagnosed with Barrett’s esophagus.  To do this, they measured fasting levels of glucose, 
insulin, leptin, and adiponectin in 392 patients previously diagnosed with Barrett’s 
esophagus.  Fasting levels of glucose were measured because it is affected by body levels 
of leptin, adiponectin, and insulin.  Duggan et al. used homeostatic model assessment 
scores (a measure of insulin sensitivity) to compare their subjects.  The results are 
tabulated in Table 1. 
Duggan et al. found that risk of developing adenocarcinoma increased as leptin 
levels increased.  Examining the data in Table 1, one can see that the relative risk of 
developing adenocarcinoma is highest in the tertile representing the greatest 
concentration of leptin (12.6-63.6 ng/mL) at all three time points measured and lowest in 
the tertile representing the least concentration of leptin (1.90-6.30ng/mL). This suggests 
an association between obesity and development of esophageal cancer since leptin levels 
are higher in obese subjects.  
When other functions of leptin are taken into account, these findings are not 
surprising.  Leptin is also known to have an anti-apoptotic and proliferative effect on 
certain intracellular signaling pathways (Ando and Catalano, 2011).  Ogunwobi et al. 
(2006) found that leptin specifically inhibits apoptosis and stimulates proliferation in 
esophageal adenocarcinoma cells,  
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Table 1. Relationship between serum concentration of leptin and adiponectin and 
relative risk for development of esophageal adenocarcinoma.  (Table taken from 
Duggan et al, 2013). 
 
 
giving further support to the idea that increased leptin puts a person at a greater 
disposition for developing esophageal cancer.  A later study by 
Howard et al. (2010) illustrated that leptin receptors were indeed upregulated in 
esophageal adenocarcinoma cells.  The anti-apoptotic nature of leptin therefore enables 
the cancer to take hold and proliferate by its own mechanism of action. 
In the study conducted by Duggan et al., adiponectin was shown to have the 
opposite effect to that shown by leptin.  The second tertile (1.26-2.45 ng/mL), not the 
third (2.46-11.46 ng/mL), was associated with the greatest risk to development of 
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adenocarcinoma in patients with preexisting Barrett’s esophagus.  This represents an 
inverse relationship: as adiponectin levels decreased, incidence of adenocarcinoma 
increased.  This again supports the positive correlation between obesity and development 
of esophageal cancer since obesity is usually associated with a decrease in adiponectin 
level. 
The effects of adiponectin on esophageal adenocarcinoma cells have been shown 
to counteract the effects of leptin.  Naturally, this antagonism has been the subject of a 
large amount of research, as a greater understanding of these processes could lead to 
therapeutic advances.  Two simultaneous studies (Konturek et al, 2008; Ogunwobi and 
Beales, 2008) illustrated this opposition of adiponectin to leptin, showing that 
adiponectin increases cell apoptosis and specifically inhibits leptin-induced proliferation 
in esophageal adenocarcinoma cells.  In this case, therefore, adiponectin can be thought 
of as an “anti-cancer” hormone and the fact that obesity is associated with a decreased 
adiponectin level further supports the conclusion that obesity increases the risk for 
development of esophageal cancer from Barrett’s esophagus.   
The Howard et al. (2010) study also measured the change in levels of adiponectin 
receptors in the same manner for which they measured the leptin receptors.  They found 
that adiponectin receptors were downregulated in a majority of tumor cells.  The result is 
that the “anti-cancer” signaling that adiponectin is able to perform is decreased, allowing 
esophageal adenocarcinoma cell proliferation to take place. 
This relationship between the level of adiponectin and development of 
adenocarcinoma may not be as straightforward as it seems.  A recent study by Almers et 
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al. (2015) found what seem to be contradictory results to those of the studies previously 
discussed.  In this study, the investigators sampled three groups of individuals: population 
controls, patients with Barrett’s esophagus, and patients with gastroesophageal reflux 
disease but no diagnosis of Barrett’s esophagus.  The levels of adiponectin were sampled 
in all three subject groups, and it was found that greater hormone levels were associated 
with a greater risk of developing Barrett’s esophagus in patients with gastroesophageal 
reflux disease.  This association was strongest in those reporting more frequent reflux 
symptoms.  No such association was found in the population control group. 
Based on the majority of the research that has been published, the results of the 
Almers et al. study do not seem to make much sense.  If obesity puts a person at a greater 
risk of developing Barrett’s esophagus, and Barrett’s esophagus puts a person at a greater 
risk for developing esophageal cancer, it follows that obesity (and all factors associated 
with obesity) should put a person at a greater risk for adenocarcinoma by the transitive 
property.  There are a few potential explanations for this supposed paradox.  One 
hypothesis is that this is an issue of timing.  It is possible that greater levels of 
adiponectin contribute to the development of Barrett’s esophagus, and that Barrett’s 
esophagus subsequently leads to a decreased level of adiponectin.  The decreased 
adiponectin then leads to development of adenocarcinoma.  This is supported by the 
finding that the association between adiponectin levels and development of Barrett’s 
esophagus is greatest when patients report more frequent reflux symptoms.  If Barrett’s 
esophagus is usually the result of prolonged reflux, it makes sense that this relationship 
would be strongest in patients that are “closest” to the Barrett’s state.  Unfortunately, this 
 23 
explanation does not account for the positive correlation between obesity and Barrett’s 
esophagus since obesity is usually associated with a lower level of adiponectin. 
It is possible that the Almers et al. study simply illustrates that the progressive 
etiology to adenocarcinoma is not as simple as obesity  gastroesophageal reflux  
Barrett’s esophagus  adenocarcinoma.  Adiponectin may only be protective if close to 
an ideal concentration.  If the Almers et al. study is correct, a concentration of 
adiponectin that is too high may put someone at a greater risk of developing Barrett’s 
esophagus and therefore esophageal cancer.  Lower concentrations of adiponectin, 
usually associated with obesity, may also lead to development of Barrett’s esophagus and 
consequently adenocarcinoma.  Only a moderate amount of adiponectin may truly be 
protective. 
 
Effects of the H. pylori Bacterium 
 
Another factor associated with obesity that may explain the link to 
adenocarcinoma is the Helicobacter pylori (H. pylori) bacterium.  This bacterium, which 
is associated with non-obese individuals has been shown to be protective against 
esophageal adenocarcinoma (Macadam et al., 2004).  Several studies have investigated 
this relationship to determine how this process works.  Understanding this bacterium’s 
protective function may be another avenue for potentially paving the way for therapeutic 
advance. 
Rubenstein et al. (2013) investigated the relationship between infection with H. 
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pylori and development of Barrett’s esophagus, erosive esophagitis, and gastroesophageal 
reflux symptoms.  To do this, they analyzed 613 men.  533 of them had undergone 
screening for colorectal cancer over a period of three years and volunteered to undergo 
the upper endoscopy required of this study.  The remaining 80 subjects were already 
diagnosed with Barrett’s esophagus in a previous examination by upper endoscopy.  This 
study was particularly interested in the cagA+ strain of the bacterium, as this was the 
strain suspected to have protective properties against reflux and its associated symptoms. 
Logistic regression was used to find an association between presence of serum 
antibodies against H. pylori or cagA and gastroesophageal reflux symptoms, Barrett’s 
esophagus, and esophagitis.  Since the production of serum antibodies represents 
interaction with foreign particles within the body, antibodies would have been produced 
to H. pylori and cagA if they had indeed entered the body at any point in the past.  
Evaluating the serum for antibodies, therefore, gives the researchers a way to track any 
previous infection.  The results of the experiment are listed in Table 2. 
The most apparent result is that the hypothesis posed by Rubenstein et al. appears 
to be correct: subjects seropositive for the antibodies against H. pylori, particularly 
antibodies against cagA, had fewer outcomes of Barrett’s esophagus and erosive 
esophagitis.  To further support this conclusion, the 80 men previously diagnosed with 
Barrett’s esophagus showed significantly fewer antibodies for H. pylori, indicating that 
they did not benefit from the apparent protective function of the bacterium. 
Of note, no association was discovered between those reporting gastroesophageal 
reflux symptoms and seropositivity of H. pylori or cagA.  This could be explained, 
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however, by the complex etiology of gastroesophageal reflux disease.  As discussed 
previously in this investigation, there are many factors that may lead to gastroesophageal 
reflux disease.  The lack of association between presence of antibodies to the bacterium 
and appearance of gastroesophageal reflux may be due to other nonrelated factors.  In 
other words, confounding variables may be at play.  Rubenstein et al. realized this and 
they stratified their subjects further.  They found that those suffering from 
gastroesophageal reflux symptoms were more likely to be obese, more likely to smoke, 
and were more likely to have hiatal hernias, all risk factors for gastroesophageal reflux 
disease.  It is likely then, that these findings do not disprove the findings of the rest of the 
experiment.  Instead, it shows that while lack of H. pylori infection may be one possible 
cause of gastroesophageal reflux disease (and therefore increase risk for 
adenocarcinoma), it is not required for the disease to take hold. 
There are a few hypotheses as to why the association found by Rubenstein et al. 
appears to be true.  The cagA+  strain of H. pylori, the focus of the Rubenstein study, has 
been shown to provoke more intense gastric mucosal inflammation.  This inflammation, 
in turn, may lead to less gastric acid secretion and therefore less opportunity for 
gastroesophageal reflux.  The mechanism for how inflammation leads to less gastric acid 
production is not entirely clear.  It could be due to local cytokine production or it could
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Table 2. Relationship between presence or absence of H. pylori and development of gastroesophageal reflux, erosive 
esophagitis, or Barrett’s esophagus.  (Table taken from Rubenstein et al, 2013). 
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be due to irreversible gastric atrophy (Beales and Calam, 1998; El-Omar et al, 1997).  
More research will need to be done in order to determine how this mechanism works.  A 
greater understanding of this process could potentially illustrate ways that H. pylori could 
be used as treatment for gastroesophageal reflux disease and its complications. 
 
H. pylori and Ghrelin 
 
It is clear that the lack of  H. pylori infection and eventual development of 
esophageal adenocarcinoma are potentially linked, but there must be several other factors 
involved.  One of these confounding factors is the presence of ghrelin, another hormone 
normally involved in the digestive process.  Ghrelin is a peptide hormone normally 
secreted from cells in the stomach itself.  In short, this hormone is the “hunger hormone” 
– its main function is to stimulate appetite.   
The most straightforward hypothesis that could explain this stimulation of 
appetite is that lower levels of H. pylori lead to an increased presence of ghrelin.  The 
increased body ghrelin would increase appetite, and this increase in appetite would 
potentially lead to obesity.  Obesity, as has been discussed extensively, puts one more at 
risk for gastroesophageal reflux disease, Barrett’s esophagus, and adenocarcinoma. 
This relationship was found by Nwokolo et al. for the first time in 2003.  In this 
experiment, Nwokolo et al. measured plasma ghrelin, leptin, and gastrin for six hours 
following an overnight fast in 10 subjects.  The results are illustrated in Figure 7. 
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Of the three hormones tested by Nwokolo et al, ghrelin was the only one to show 
significant change after H. pylori infection was eradicated.  Levels of gastrin and leptin 
did not change significantly.  Ghrelin, therefore, must be most closely linked to infection 
by this bacterium.  Significant increases in ghrelin level would, as previously mentioned, 
increase a subject’s appetite and potentially lead to obesity.  If this mechanism holds true, 
H. pylori may not be the sole cause of adenocarcinoma – it may only be a contributing 
factor for development of this cancer.  It is also worth noting that Nwokolo et al. found 
that curing their subjects of H. pylori infection also led to a significant increase in gastric 
acid secretion.  Again, this may not be simply a cause and effect relationship.  If 
Figure 7. Serum ghrelin level significantly increases 
following cure of H. pylori infection.  Nwokolo et al. found 
that ghrelin levels increase significantly following eradication 
of the H. pyloribacterium.  While slight decreases in leptin 
and gastrin were also found, these results were not deemed 
statistically significant.  Intragastric acidity also increased 
significantly, suggesting that eradication of H. pylori may be 
linked to increased gastroesophageal reflux by some 
mechanism.  (Figure taken from Nwokolo et al, 2003). 
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increased ghrelin leads to increased appetite, then the extra food needing to be digested 
would ultimately signal the body to produce more gastric acid.  This could be the 
mechanism by which ghrelin leads to increased risk of gastroesophageal reflux and 
therefore Barrett’s esophagus and adenocarcinoma. 
A simultaneous study conducted in 2003 by Gokcel et al. found results 
completely contradictory to those published by Nwokolo et al.  In this study, Gokcel et al. 
took biopsy specimens during gastric endoscopy from 39 women, matched for potential 
confounding variables such as age and body mass index.  Fifteen of the subjects were 
found to be H. pylori negative and the remaining 24 women were positive for H. pylori.  
Their results, including the variables for which their subjects were matched, are tabulated 
in Table 3. 
No significant differences were found between any of the variables measured in 
the Gokcel experiment.  These results clearly are at opposition with the results found by  
Nwokolo et al.  While Gokcel is not saying that H. pylori does not have an impact on 
development of esophagitis or Barrett’s esophagus, it does raise questions about whether 
or not ghrelin is involved.  It is also worth pointing out that this study included a larger 
subject pool than the study conducted by Nwokolo.  Gokcel’s study, therefore, has more 
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Table 3. No significant difference was found by Gokcel et al. in serum ghrelin 
level between H. pylori negative and H. pylori positive subjects (Table taken from 
Gokcel et al, 2003). 
 
statistical power.  While this does not prove that one study is superior to the other, it does 
certainly encourage further research on the relationship between ghrelin and H. pylori. 
The relationship between ghrelin and development of Barrett’s esophagus and 
adenocarcinoma remains unclear.  In 2013, Rubenstein et al.’s study also investigated the 
impact of ghrelin on Barrett’s esophagus and esophageal adenocarcinoma.  What they 
found confirms that the exact mechanism of action is still unknown to us.  In their study, 
ghrelin appeared to protect against gastroesophageal reflux.  Based on the results of the 
previously discussed studies, the opposite would be expected.  If ghrelin increases 
appetite, which increases gastric acid production, it does not make sense for ghrelin to 
decrease reflux symptoms.  Rubenstein et al. hypothesized that ghrelin’s ability to 
facilitate gastric emptying may override the tendency for ghrelin to increase gastric acid 
production.  They note that ghrelin may antagonize the development of gastroesophageal 
reflux disease, but through the production of growth hormone may still promote the 
development of Barrett’s esophagus. 
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In 2007, de Martel et al. investigated the direct link between serum ghrelin levels 
and the risk of esophageal adenocarcinoma.  The results of the de Martel study were 
consistent with the findings of the Rubenstein study.  The de Martel investigation 
originally hypothesized that decreased serum ghrelin during H. pylori infection would 
protect against cancer of the esophagus.  What they found was that high serum ghrelin 
was protective against adenocarcinoma, not the opposite.  Interestingly, they found that 
this relationship only held true for subjects with body mass index greater than or equal to 
25kg/m
2
.  They also found that the effects of H. pylori and ghrelin were independent, 
supporting the work of Gokcel et al. 
A potential explanation for ghrelin’s complicated relationship with development 
of adenocarcinoma could again be one of timing.  The relationship between H. pylori and 
ghrelin remains unclear, but it seems that there is at least some correlation between 
ghrelin and development of esophageal cancer.  It is likely that ghrelin, which is known 
to increase appetite, has some impact on obesity.  Obesity may cause reflux independent 
of an increase in gastric acid production.  Therefore, Barrett’s esophagus may result over 
time due to a number of these factors.  This is supported by the Rubenstein study, which 
still illustrates a positive correlation between increased ghrelin production and increased 
risk for Barrett’s esophagus.  Once Barrett’s esophagus has developed, obesity may still 
be present and ghrelin levels may remain high.  If ghrelin does protect against 
adenocarcinoma in subjects with high body mass indices, it is possible that this is the 
time at which this protective effect occurs.  As stated previously, most patients with 
Barrett’s esophagus do not go on to develop esophageal cancer.  It is possible, therefore, 
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that ghrelin could be another treatment avenue for preventing the onset of 
adenocarcinoma in Barrett’s patients. 
This proposed treatment would present some problems.  Most people who are 
suffering from obesity are looking forward to advances in the field of dietary medicine.  
They yearn for a day when they can take a drug that will lead to dramatic weight loss.  
Since ghrelin has been linked with appetite, it is naturally one of the major avenues of 
study for finding a treatment for obesity  (Chollet et al, 2009).  If ghrelin does indeed turn 
out to be the key to developing a drug for adenocarcinoma, patients may have to sacrifice 
weight loss for prevention of esophageal cancer.  The problem is that obesity comes with 
its own related health problems and both obesity and adenocarcinoma come with high 
mortality rates.  Finding a way to target the proposed ghrelin drug for adenocarcinoma 
may be the answer.  It is clear, however, that a greater understanding of ghrelin’s role in 
the etiology of esophageal adenocarcinoma must be achieved before a large amount of 
work can be warranted in this arena. 
 
Other Lifestyle Factors 
 
In general, it is widely accepted that smoking is a risk factor for both development 
of Barrett’s esophagus and esophageal adenocarcinoma.  The exact relationship between 
smoking, obesity, and development of these diseases, however, is still not yet completely 
understood. 
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In 2012, Coleman et al. investigated whether or not there is a correlation between 
smoking habits and risk of developing esophageal adenocarcinoma.  They analyzed 
hospital case notes of 3,167 patients in Northern Ireland who had been previously 
diagnosed with Barrett’s esophagus.  They noted the dates of diagnosis, and paid special 
attention to reported lifestyle choices, including tobacco use.  Their results are compiled 
in Figure 8. 
Of those who had a history of smoking, the patients that previously quit smoking 
were at lower risk of developing adenocarcinoma than those who were current smokers.  
This suggests a few conclusions.  First, it implies that while smoking does put a person at 
greater risk of developing adenocarcinoma, it must do so at a gradual rate.  A one-time 
smoker is, if this data is correct, less likely to contract adenocarcinoma than a long term  
 
Figure 8. Plot comparing time since diagnosis of Barrett’s 
esophagus and progression towards adenocarcinoma 
based on smoking habits.  It was found that smokers were at 
greater risk of developing adenocarcinoma among those 
previously diagnosed with Barrett’s esophagus.  Current 
smokers were at greater risk than former smokers.  (Figure 
taken from Coleman et al, 2012). 
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smoker.  Second, it also suggests that cessation of smoking may halt, or potentially 
reverse, damage to the lower esophagus.  In order to determine if this assumption is 
correct, duration and intensity of smoking habits would have to be studied. 
Coleman et al. attempted to collect this information, but duration (number of 
years smoked) and intensity (number of cigarettes smoked per day) of smoking habits 
were not shown to have a significant impact on progression to adenocarcinoma.  It must 
be noted, however, that this information was not widely reported among the subjects who 
participated in this experiment.  Number of years smoked was only known for 17% of 
individuals, and intensity of smoking habits was only known for slightly more than half 
of the participants in the study. 
Other lifestyle factors and variables were also looked at in the Coleman study.  
Alcohol intake was reported for about 70% of the study participants, but it was not shown 
to have a significant bearing on the progression from Barrett’s esophagus to 
adenocarcinoma.  Few patients in the study had both height and weight recorded.  For 
these subjects, body mass indices were calculated, and it was found that 75% of those 
who progressed to adenocarcinoma and 68% of those who did not progress could be 
classified as obese.  This did not represent a statistically significant difference.  This may 
have been due to the limited sample size, but it also may shed light on the impact of 
smoking on development of esophageal cancer.  Smoking may put someone at a greater 
risk of developing adenocarcinoma than obesity, though further research would need to 
be conducted in order to determine if this is truly the case. 
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Although smoking is usually regarded as a risk factor for Barrett’s esophagus as 
well as adenocarcinoma, this relationship appears to be much more complicated.  Similar 
to the research being done on H. pylori and ghrelin, the results of studies looking into this 
potential correlation are somewhat contradictory. 
In 2013, Balasubramanian et al. analyzed 1,056 patients suffering from 
gastroesophageal reflux.  All subjects completed a questionnaire which included 
questions on demographic information, cigarette smoking (amount, current/past, and 
duration), clinical data, and endoscopic findings (Barrett’s esophagus, hiatal hernia, etc.).  
The study looked at two main relationships.  The first was whether duration of smoking 
had any impact on the relative risk of developing Barrett’s esophagus.  The second was 
whether time since cessation of smoking had any correlation with the relative risk of 
developing Barrett’s esophagus.  The results are compiled in Figure 9. 
The results of the Balasubramanian experiment were not surprising.  The longer 
the duration of a person’s smoking habits, the greater the risk of developing Barrett’s 
esophagus.  The length of time since a subject stopped smoking had an inverse 
relationship with risk of developing Barrett’s esophagus.  These results support the 
findings of the Coleman study.  Since Barrett’s esophagus is the precursor to 
adenocarcinoma, it makes sense that smoking would be a risk factor for both the cancer 
and its precursor. 
Unfortunately, these results have not been consistently replicated.  In two 2014 
studies, it was shown that there is no association between smoking habits and 
development of Barrett’s esophagus. 
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Yates et al. (2014) conducted a study of 104 participants and found that obesity 
had a significant association with development of Barrett’s esophagus, but found no 
significant association between risk for Barrett’s esophagus and lifestyle habits such as 
smoking and alcohol consumption.  The data collected in the Yates study is reproduced in 
Table 4. 
The Yates study did have one additional finding of interest.  When stratifying 
subjects by type of alcohol consumed (wine vs. beer vs. spirits), borderline significance 
was found (p = 0.06) for a relationship between development of esophageal 
adenocarcinoma and wine consumption.  An inverse relationship was found between the 
two factors.  In other words, it was suggested that wine may have a protective effect on 
the development of adenocarcinoma.  No association, however, was shown between wine 
consumption and risk for Barrett’s esophagus.  It is possible then, that wine helps to 
prevent the dysplasia associated with development of cancer, but not the initial 
metaplasia needed for a diagnosis of Barrett’s esophagus.  More research will have to be 
done in order to determine if wine truly does have a protective effect on the development 
of adenocarcinoma. 
The second 2014 study, conducted by Thrift et al, also determined that overall 
smoking and alcohol consumption have no significant bearing on the risk for developing 
Barrett’s esophagus.  Like the Yates study, the Thrift study also stratified alcohol 
consumption by type of alcohol. 
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Figure 9. Smoking duration and years since cessation has 
a direct impact on risk for Barrett’s esophagus.  It was 
found that years of cigarette smoking had a direct correlation 
with the odds of contracting Barrett’s esophagus.  Similarly, it 
was found that years since quitting smoking had an inverse 
relationship with risk of developing Barrett’s esophagus.  
(Figure taken from Balasubramanian et al, 2013). 
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Table 4. Relationship between lifestyle factors and risk of developing 
Barrett’s esophagus. Body mass index was shown to have a significant 
relationship with risk of developing Barrett’s esophagus (p<0.05).  Smoking and 
alcohol use were not found to have significant relationships with risk of 
developing Barrett’s esophagus. (Table taken from Yates et al, 2014). 
   
The Thrift study found that moderate (14-<28 drinks per week) intake of beer 
corresponded with lower risk of developing Barrett’s esophagus.  This contrasts with the 
Yates study, which found such an association only for intake of wine. 
It can be concluded that the impact of lifestyle habits on the development of 
Barrett’s esophagus and adenocarcinoma are incredibly complex.  Current research has 
not been able to determine a trend that is consistent.  Further research will have to be 
conducted in order to further elucidate these connections. 
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Genetic Predisposition 
 
While the majority of this investigation has dealt with more modifiable risk 
factors, the remainder will discuss inherited risk factors, namely those that can be 
analyzed through the use of genetics.  The study of genetics, especially in relation to 
development of Barrett’s esophagus and adenocarcinoma is still very new.  As research 
continues into the possibility of using genetic therapy to treat disease, research into the 
genetic causes of these diseases may shed some light on new targeted therapies. 
It has been well-established that there is a genetic component to obesity.  Thrift et 
al. (2014) conducted a “Mendelian randomization” to determine whether or not genetic 
risk for obesity can be associated with development of Barrett’s esophagus and 
esophageal adenocarcinoma.  Mendelian randomization assumes that previously 
identified genetic markers for a certain trait (in this case, obesity) are analogous to 
phenotypes observed in the population.  For instance, if a person has a very high genetic 
risk for obesity, then that person is considered to have a higher lifetime body mass index. 
The benefits of using such an approach are many.  The most important benefit to 
conducting a study utilizing Mendelian randomization is the elimination of bias.  
Genetics cannot be confounded by environmental variables.  In this instance, a 
predisposition to obesity should show a link to Barrett’s esophagus and adenocarcinoma 
if such a link exists.  Other potential risk factors that have been previously discussed, 
including lifestyle habits, hormonal changes, and H. pylori infection, will not affect the 
results. 
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In order to increase the power of their study, Thrift et al. used multiple known 
genetic variants that have been previously linked to high body mass indices.  They found 
that, as expected, higher genetic risk for obesity was associated with presence of 
esophageal adenocarcinoma, seemingly confirming that a link exists between the two 
states.  Interestingly, the statistical significance disappeared among women when subjects 
were stratified based on gender.  A similar trend was noted for the risk for Barrett’s 
esophagus.  Thrift et al. found that there was a 12% increased risk for Barrett’s esophagus 
for every 1 kg/m
2
 predicted increase in body mass index among the subjects in this study.  
This trend was statistically significant even when subjects were stratified by gender. 
The Thrift study seems to confirm that people who have a higher genetic pre -
disposition to obesity have a greater chance of contracting Barrett’s esophagus and 
esophageal adenocarcinoma than those who are not.  Since this study was done via 
Mendelian randomization, it suggests that obesity has an impact on development of these 
disease states independently of other risk factors 
Of course, it cannot be that simple.  Other investigators have noted that studies 
like the one carried out by Thrift et al. have primarily focused on a European population.  
As noted by Abrams and Chak in 2014, Barrett’s esophagus and esophageal 
adenocarcinoma seem to occur in those of European descent far more than in other 
populations.  Obesity on its own, however, is more prevalent in African-American 
populations than it is in European populations.  Based on the genetic research carried out 
by researchers like Thrift, it would make sense if African-Americans therefore suffered a 
higher incidence of adenocarcinoma and Barrett’s esophagus than those of European 
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descent, but this is not the case.  Further studies will need to be done in order to 
determine whether or not the same genetic risk scores are predictive of obesity, Barrett’s 
esophagus, and adenocarcinoma in more heterogeneous populations. 
Other researchers have tried to elucidate more direct genetic predispositions to 
Barrett’s esophagus and adenocarcinoma.  It has been found that two tumor suppressor 
genes, CDKN2A and TP53, are frequently mutated in esophageal adenocarcinoma 
tumors.  Buas et al. (2014) conducted a genome-wide association study of 5,722 subjects, 
2,515 of which were positive for esophageal adenocarcinoma.  They analyzed 37 
different single nucleotide polymorphisms at these loci for their study.  Single nucleotide 
polymorphisms, usually referred to as SNPs, occur when a single nucleotide in a DNA 
sequence is variable in a population.  SNPs are the most common type of genetic 
variation in the population. 
Of the 37 SNPs at the loci studied by Buas et al., three were shown to be 
associated with risk of esophageal adenocarcinoma (Table 6).   Two of the variants, 
rs2518720 and rs3088440, were observed to be significantly associated with reduced risk 
of developing esophageal cancer.  The third SNP, rs4074785, was also shown to be 
associated with reduced risk of adenocarcinoma, but at borderline significance. 
Buas et al. decided to further investigate rs3088440, one of the SNPs shown to be 
significantly associated with reduced risk of esophageal cancer.  Specifically, they noted 
that this polymorphism is characterized by a transition from guanine to alanine.  They 
found that this polymorphism may disrupt a binding site for a particular noncoding RNA 
molecule (Figure 10).  Since mRNA would need to bind to this site in order to complete 
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the transcription process, this could effectively slow down protein synthesis.  In general, 
cancer cells are known to increase transcription and translation of growth factors in order 
to continue growing and proliferating.  By blocking the transcription process, individuals 
with this SNP may not be able to host cancer cells as effectively because the machinery
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Table 5. Three SNPs were shown to have an association with reduced risk of progression from Barrett’s esophagus to 
esophageal adenocarcinoma.(Table taken from Buas et al., 2014). 
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needed to nurture those cells is not functioning effectively.   
It is not as clear how the other two identified SNPs, rs4074785 and rs2518720, 
may affect progression to esophageal adenocarcinoma.  These two SNPs, unlike the 
previously discussed SNP, are located in intronic sections of the genome.  Generally, 
intronic sections of the genome are less understood than those in the functional exons.  It 
is known that certain intronic sections are enhancers to exonic sections.  Depending on 
where the SNPs are located on the introns, they may also affect the splicing process 
during post-transcriptional modification. 
 
 
 
 
 
 
 
 
 
 
Figure 10. The rs3088440 SNP disrupts the binding site of 
miRNA during transcription.  By transition of a G to an A, 
the binding of miRNA has one less connection to the 
transcribed protein, causing a weaker process and potentially 
decreasing the viability of a potential cancerous cell.  (Figure 
taken from Buas et al, 2014). 
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A Potential Reversal of Barrett’s Esophagus 
 
When an individual is diagnosed with Barrett’s esophagus, they are not told that it 
is a condition that can be reversed.  The patient is warned of the potential dangers of the 
disease, and its association with esophageal adenocarcinoma.  They are given a list of 
lifestyle modifications that may stave off esophageal cancer, but the metaplasia that has 
already taken hold is considered irreversible. 
By gaining a greater understanding of the risk factors and etiology of esophageal 
adenocarcinoma, we may be able to change this outlook.  If Barrett’s esophagus is truly a 
pre-cancerous state, our focus should be on curing Barrett’s before the dysplasia 
associated with the cancer occurs. 
The most common non-surveillance treatment for Barrett’s esophagus today is 
surgery.  Caygill et al. (2011) noted that decreasing the gastroesophageal reflux may 
cause reversal of Barrett’s esophagus cells.  A Nissen fundoplication, as described 
previously, could decrease symptoms of gastroesophageal reflux by tightening the 
opening of the lower esophageal spincter.  Unfortunately, the results of antireflux surgery 
have been mixed.  While some patients have reported a reversal of metaplasia, still others 
have gone on to develop adenocarcinoma. 
For this reason, Caygill et al. recommends that patients who undergo antireflux 
surgery still go to regular appointments with their gastroenterologists for routine 
monitoring of the lower esophagus.  Surgery, therefore, is not a surefire way to cure 
Barrett’s esophagus and it is clear that other avenues must be explored. 
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A few recent studies have begun looking into other methods of treating Barrett’s 
esophagus in order to prevent the onset of cancer.  Inge et al. (2013) investigated the 
effects of Dasatinib, an inhibitor of the Src kinase, on Barrett’s esophagus cell lines.  Src 
kinase is what is termed a “proto-oncogene”.  A proto-oncogene is a normal gene that can 
become an oncogene (a pre-cancer gene) if it becomes dysfunctional.  What they found 
was that Dasatinib reduced activation of the Src kinase, reducing phosphorylation of p27.  
p27 is a tumor suppressor (a molecule that normally functions to reduce genesis of 
tumors).  When phosphorylated, p27 loses its ability to regulate cell proliferation. 
Increasing the amount of active p27 led to decreased proliferation, arrest of the 
cell cycle, and activation of apoptosis (Table 6).  The cell cycle is comprised of multiple 
phases.  The two phases of interest to this experiment were the G phase and the S phase. 
The G phase is essentially a “rest” phase in which the cell is not actively undergoing the 
processes needed to replicate.  The S phase is the phase in which the cell is replicating its 
DNA in preparation for proliferation.  As treatment time increased, the Barrett’s  
 
 
 
 
Table 6. Dasatinib induces cell cycle arrest at G1 in 
Barrett’s esophagus cells.  As time of treatment in hours 
(top) increases, the percentage of cells arrested at G1 
increases. (Table taken from Inge et al, 2013). 
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esophagus cells were arrested in the G1 phase, meaning that they were no tallowed to 
progress to the stage in which DNA replication could take place.  While more research 
needs to be done on the potential effects of Dasatinib, the results of this study are 
promising.  This drug could be a pharmacological means of halting the progression of 
Barrett’s esophagus. 
One of the newest potential approaches for treatment of Barrett’s esophagus is 
cryotherapy.  In 2011, Xue et al. conducted a pilot study to determine the efficacy of 
cryotherapy by pressurized carbon dioxide gas in patients suffering from Barrett’s 
esophagus.  They enrolled 22 patients into their study, 20 of which completed the 
treatment.  The treatment constituted stepwise cryoablation with the pressurized gas.  
Most patients underwent two treatments in order to eradicate the Barrett’s esophagus 
metaplastic cells. 
Once the cryogenic spray was applied, ice immediately formed on the esophageal 
mucosa.  Once the cryoburn of the formed ice abated, the mucosa of the lower esophagus 
began to erode.  Patients did not report any significant adverse events during treatment.  
After cryoablation treatment was complete, the Barrett’s esophagus cells were no longer 
present (Figure 11). 
Of the patients that completed the treatment, only three showed recurrence of 
Barrett’s esophagus cells after six months.  While this was only a pilot study that 
involved a limited number of participants, the implications are quite astounding.  The rate 
of success of this treatment in this initial study was high (85%) and further improvements 
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to the technology may improve the outcome still.  Cryotherapy seems to be a promising 
field that may help to turn the tide against rising incidence of adenocarcinoma.  
 
 
 
 
 
Figure 11. Endoscopic images of the lower esophagus in a 
52-year old male before and after treatment with 
cryotherapy. Before cryotherapy, this patient had a 2 cm. 
segment of Barrett’s esophagus (a).  After three 
cryotherapy sessions, the lower esophagus resumed its 
normal appearance and the Barrett’s esophagus cells were 
not present (b). (Figure taken from Xue et al, 2011). 
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CONCLUSIONS 
 
After conducting this investigation, it is clear that we still do not understand the 
complex relationship that defines the etiology of esophageal adenocarcinoma.  Several 
potential risk factors have been identified, many of which are modifiable.  These 
modifiable risk factors include obesity, hormonal changes, H. pylori infection, and 
lifestyle habits such as smoking.  Recently, it has also been found that there are genetic 
factors at work that may predispose individuals to certain risk factors for esophageal 
adenocarcinoma.  It has also been postulated that genetics can predispose a person to 
Barrett’s esophagus or adenocarcinoma directly.  Many studies of these risk factors are 
still producing conflicting results, so it is possible that there are other variables that are 
not yet being considered.   
Researchers must continue to study these risk factors extensively in order to find 
potential new treatments for Barrett’s esophagus.  While there have been some recent 
advances, including the advent of cryotherapy, researchers and physicians still have a 
long way to go before Barrett’s esophagus and adenocarcinoma are no longer a problem.  
Further research into the true mechanism that underlies the transition from metaplastic 
Barrett’s cells to dysplastic cancerous cells will be key in our understanding of the 
disease process and future treatment regimens.    
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